Floatz logo

Cbe

Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations

Calithera Biosciences, IncPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations cohort.

Asset / SponsorPhaseRating
Bms-907351
Calithera Biosciences, Inc
Phase 1CC
Telaglenastat
Calithera Biosciences, Inc
Phase 1CC

Same molecule, other indications

Cbe is also rated in:

gastrointestinal stromal tumorDormant
CC
Indicative ·
47 / 100
View asset →
fumaric aciduriaDormant
CC
Indicative ·
47 / 100
View asset →
Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal TumorsDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →